In recent developments, Chardan Capital has released an update regarding 4D Molecular Therapeutics (FDMT, Financial). The analyst firm, represented by Geulah Livshits, continues to maintain a "Buy" rating for the biotech company. This decision indicates continued confidence in the company's potential despite some adjustments.
In the latest report dated May 9, 2025, Chardan Capital lowered the price target for FDMT from a prior target of $28.00 to a new adjusted target of $25.00. This change represents a decrease of approximately 10.71% in the price target, reflecting adjustments in market expectations or company performance considerations.
The currency for the price target is denoted in USD, and the stock continues to trade on the NASDAQ exchange under the ticker FDMT. The consistent buy rating suggests that Chardan Capital sees long-term growth opportunities for 4D Molecular Therapeutics, even with the revised price target.
Investors and market watchers may want to keep an eye on FDMT shares, as the "Buy" recommendation indicates potential upside despite the lowered price target. This update could prompt further analysis by stakeholders looking to understand the implications of the adjusted price forecast.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 10 analysts, the average target price for 4D Molecular Therapeutics Inc (FDMT, Financial) is $28.50 with a high estimate of $44.00 and a low estimate of $6.00. The average target implies an upside of 825.32% from the current price of $3.08. More detailed estimate data can be found on the 4D Molecular Therapeutics Inc (FDMT) Forecast page.
Based on the consensus recommendation from 11 brokerage firms, 4D Molecular Therapeutics Inc's (FDMT, Financial) average brokerage recommendation is currently 2.1, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for 4D Molecular Therapeutics Inc (FDMT, Financial) in one year is $0.05, suggesting a downside of 98.38% from the current price of $3.08. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the 4D Molecular Therapeutics Inc (FDMT) Summary page.
